Where Next-Generation Metabolic Therapies Begin
Diasome is advancing a new class of medicines that restore the body’s natural physiology. Our HDV™ platform enables cell specific delivery, offering scalable improvements in how drugs are developed and how care is provided.
.avif)
A team anchored by deep cardiometabolic expertise
Since its founding in 2012, Diasome has been a scientifically driven organization that focuses on translating novel therapeutic insights to develop innovative medicine for diabetes, obesity, and metabolic diseases.
Our core technology platform harnesses endogenous mechanisms to resolve metabolic dysregulation across a broad range of diseases.
.avif)
"When we deliver medicines to the right metabolic pathways, we unlock their full potential—improving both how they work and who they can help."
Robert Geho, MBA
Co-Founder, Chief Executive Officer
Meet our team
Robert Geho, MBA
CO-FOUNDER, CHIEF EXECUTIVE OFFICER
W. Blair Geho, MD, PhD
CO-FOUNDER, CHIEF SCIENTIFIC OFFICER
Horacio Plotkin, MD
CHIEF MEDICAL OFFICER
Paul Strumph, MD
MEDICAL DIRECTOR
Caroline El Sanadi, PhD
DIRECTOR, TECHNICAL & RESEARCH OPERATIONS
Kent Manson
VP, STRATEGY & COMMERCIAL DEVELOPMENT
Board of Directors
Frank McCaney
INDEPENDENT DIRECTOR
W. Blair Geho, MD, PhD
CO-FOUNDER, CHIEF SCIENTIFIC OFFICER
Robert Geho, MBA
CO-FOUNDER, CHIEF EXECUTIVE OFFICER
Thomas McDonald
McDonald Partners
Cosme Ordonez, MD
Aegis Capital
Peter Tollman, PhD
BOARD CHAIRMAN
Eric Edidin
OBSERVER
Endo Investors
Daniel Flicker, PhD
OBSERVER
Breakthrough T1D Fund
Josh Hexter
OBSERVER
Oramed Pharmaceuticals
.jpg)
.jpg)